Press Releases

For Immediate Release
St Paul Minnesota, September 16, 2011 - Gamma Pharmaceuticals, Inc. (NASDAQ: GMPM.PK), a vitamin and nutriceuticals marketing and product formulation company,  announced today that on September 13, 2011, shareholders holding 52.04% of the outstanding shares of common stock of Gamma Pharmaceuticals Inc. (“Gamma”) removed Hao Zhang from Gamma’s Board of Directors. The removal did not result from any disagreement between Hao Zhang and the other Directors of the company.  Rather, Hao Zhang had been inactive as a Director of Gamma for some time as a result of Gamma’s deferral of plans to enter the Chinese market. 

Gamma also announced it moved its headquarters from Las Vegas, NV, to St. Paul, MN, effective immediately. The Company hopes to leverage Minnesota’s reputation and exceptional resources for healthcare and consumer products companies.  The Company sites a skilled workforce, good schools and a generally better infrastructure on which to anchor its global business.   For a small but growing company, with tentacles reaching across the country and global aspirations, Minnesota's central location, time zone and airport are a further draw.  Gamma hopes to attract the best marketing, sales and formulation professionals, as well as build strategic partnerships with local companies. 

Gamma’s new address is the following:

Gamma Pharmaceuticals Inc
855 Village Center Drive
#355
St. Paul, MN 55127-3016

About Gamma Pharmaceuticals Inc

For Immediate Release
LAS VEGAS, Aug. 15, 2011 /PRNewswire/ -- Gamma Pharmaceuticals Inc. (NASDAQ:GMPM.PK - News), a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, announced today, the Company accepted purchase orders from three counterparties and expects more in the weeks to come.  The Company also signed a distribution agreement for the South-central and the Southwest US market.  Importantly, Gamma completed a manufacturing run for its Gamma Energy Gel™, which will be in retail outlets in the New York metropolitan region, Northern California and Texas.  

Individually, each of these accomplishments is a noteworthy achievement in the Company's annual plan; collectively, they represent a significant step forward.  The Company is utilizing the credit facility announced earlier this year to finance working capital.

About Gamma Pharmaceuticals Inc

For Immediate Release
Las Vegas, Nevada, June 21, 2011 - Gamma Pharmaceuticals, Inc. (NASDAQ: GMPM.PK), (“Gamma” or the “Company”,) a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally, announced a special meeting for its shareholders. 

TO OUR STOCKHOLDERS:

Over the past few months, in particular, we have had numerous phone calls from stockholders stating their obvious concerns over the lack of ongoing communication regarding our Company’s progress and the overall performance of our Common Stock.  These two factors have led many of those with whom we have spoken to express concern over the overall “health” of our company and its prospects in this difficult economic environment. 

To that end, Gamma’s Board of Directors (the “Board”) have organized a Special Shareholders Meeting on July 9, 2011 commencing at 1:00pm at the Bellagio Resort, Las Vegas. 

The purpose of the meeting is to provide a forum for Gamma’s current investors to discuss the direction of the Company in the months ahead and to review Gamma’s recent operating history, reflecting the Company’s effort to enhance investor communications.  Each participant will require a ticket to gain entrance to the meeting and a dial-in number can be made available.   Those wishing to attend or to participate by conference call may contact Gamma’s CFO, Joseph Cunningham at (651) 204-2048 or by email at jcunningham@gammapharma.com

The recent past has been challenging for Gamma, but the Company has begun to clear the road ahead of most obstacles and Board looks forward to an open and candid discussion on Gamma’s future.  The Board is grateful to Gamma’s investors as the Company continues the journey upon which we embarked.   The Board of Directors looks forward to having a good turnout on July 9th and we thank you in advance for your participation in this important meeting. 

Best regards,

The Board of Directors, Gamma’s Pharmaceuticals Inc

About Gamma Pharmaceuticals Inc

For Immediate Release
Las Vegas, Nevada, June 8, 2011 - Gamma Pharmaceuticals, Inc. (NASDAQ: GMPM.PK), a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally. 
Gamma’s management is pleased to communicate our recent developments and to provide important information to our shareholders on our progress, as the company gains commercial traction.  Please note the following:
Sales and Distribution Achievements
Gamma began shipping products to a major national retail chain in April, and is working with their management to put in place additional orders for +/- 8000 outlets.  Gamma can strategically launch products in this chain’s outlets by region, providing the Company with a more cost-effective path into a major national account. 
Gamma just appointed distributors to service territories in California, Texas and selected locations in the Southeastern US.  These distributors have placed pro-forma orders for Gamma energy products and are awaiting completion of a manufacturing run currently underway.  Negotiations continue with other distributors in several territories across the US.
Gamma’s relationship with the Company’s major distributor, announced last year, remains intact.  They have waited patiently while Gamma management has worked to put in place production financing arrangements sufficient to meet the unit forecasts agreed and the roll-out marketing programs.   
Last month, Gamma signed a contract for export sales and is awaiting receipt of a 50% deposit.   Contract terms call for a deposit paid to Gamma of 50% of the value of the order with full payment due at completion of manufacture, prior to shipment.  Gamma has received the sales order documentation and is waiting for the deposit to commence manufacturing. Management has several other export negotiations underway. 
Production Financing to support Sales and Distribution Achievements
Gamma has just negotiated a private production financing arrangement (“Credit Facility”) with one of the Company’s trusted shareholders.  This non-exclusive, off-balance-sheet vehicle can initially provide the Company with the operational liquidity necessary to fund inventory and to meet current expenses. Distributors have recently placed pro-forma purchase orders and inventory reservations with Gamma; Gamma has utilized the Credit Facility to pay suppliers.  Manufacturing is now underway to meet these orders.

Current Focus
Gamma’s focus is narrow and it is specific:  sales, manufacturing and financing.  The product pipeline is fully developed and has been revised sufficiently to attract retailers, distributors and consumers.  Closely working with distributors and retailers to continue product rollout should achieve in–market sales   sufficient to fund the brand marketing programs.  The Company’s Credit Facility will fund product production and meet working capital needs. 
Financing
Traditional equity financing has not been available, despite Management’s best efforts. Gamma is diligently working with a variety of parties to secure financing and improve the Company’s balance sheet.  There are approximately 63-million common shares outstanding with management controlling approximately 53% of the outstanding stock.  No stock has been issued in nearly 18-months; but stock will be issued in conjunction with deployment of the Credit Facility.
Audit, SEC Filings and Shareholder Meeting
Coming current with Audit and SEC filings is one of Management’s top priorities.  Gamma has continued to operate the business as if it were audit compliant.  The audit process will be funded by current cash flow from product sales.  Due to the low-level of commercial activity these past two years, no substantial audit issues are expected.  The company intends to come current with its SEC filings and hold an annual general meeting later this year.
Other Developments
Gamma is moving forward with its own branded energy products.  Gamma is now procuring orders and manufacturing its own range of energy products under the Gamma Energy brand.  Gamma watchers may recall the Company converting its licensing agreement for energy products with Jugular Inc., into a joint venture last year.   This joint venture has not performed as expected.  Jugular Inc. has a vision and is trying to create an image for the brand that Management has determined, does not resonate well with Gamma’s target audience.  A dispute has arisen and the arrangement has been sidelined.  In addition, in 2010, the Company announced a global product development and marketing joint venture with a world famous athletic personality. This joint venture also has also not performed to either party’s expectations and ended amicably earlier this year.
As Gamma gains commercial traction, Management continues to work diligently to source sales opportunities and to develop the Company to meet investors’ expatiations.  Management believes that the Company has gained a foothold into a key retail channel.  This traction, when combined with other distributors and retail opportunities, can provide a growth profile consistent with Gamma’s peers.  Management will seek closer communication with investors and stakeholders but otherwise invites inquiries to the Company’s corporate headquarters. 

About Gamma Pharmaceuticals Inc

For Immediate Release
LAS VEGAS, NV--(Marketwire - 09/24/10) - Gamma Pharmaceuticals, Inc. (Pinksheets:GMPM - News): Gamma Pharmaceuticals Inc. (“Gamma” or the “Company”) announced today the shipment of products pursuant to the purchase order announced August 16, 2010. Gamma also announced today that the Company has booked revenue for the transaction representing the Company’s first significant revenue achievement in nearly two years and signifying the success of Gamma’s turnaround strategy implemented by management earlier this year. The purchase order was the first of many expected pursuant to a distribution agreement announced March 3rd, 2010 that guarantees Gamma minimum monthly product sales volume translating into approximately $48.0 million in annualized sales. This order has been shipped to U.S. retail chains located in the upper Midwest region. Gamma is in the process of fulfilling additional purchase orders and pursuing retail channel opportunities nationwide.

Gamma’s CEO Peter Cunningham commented, “We are very pleased to have finalized our contract manufacturing, distribution infrastructure and transaction process with our partners, resulting in a successful production, sales and revenue cycle. Gamma again extends its heartfelt gratitude to our key distribution partner, and we look forward to further executing the ramp-up phase in Gamma’s business plan, which will accelerate in the months ahead. We will drive revenues from a variety of wholesale distributors and food, pharmacy, discount and convenience store retailers as we expand geographically, add additional products and sign-on additional distribution partners and retailers. Importantly, our suppliers have been equally supportive of our turnaround strategy and our go-to-market programs.”

On March 3, 2010, Gamma announced that the Company had entered into a multi-year agreement (the “Agreement”) with one of North America’s leading wholesale distribution organizations to distribute the full line of Gamma products. The Agreement, which is evergreen in duration, provides for minimum monthly volume purchases of Gamma products at agreed upon pricing per SKU. The contracted terms prescribe a minimum purchase of 40,000 cases per month (after an initial ramp-up period) of Gamma’s branded products, which at full distribution equates to annualized sales revenue of approximately $48.0 million. Gamma’s distribution partner is a large wholesale distributor of some of the most well-known and successful branded consumer products in North America, and is credited with contributing to the commercial success of many leading consumer brands.

About Gamma Pharmaceuticals Inc

For Immediate Release
LAS VEGAS, NV--(Marketwire - 08/16/10) - Gamma Pharmaceuticals, Inc. (Pinksheets:GMPM - News): Gamma Pharmaceuticals Inc. (“Gamma” or the “Company”) announced that manufacturing is under way for several of its product lines pursuant to customer purchase orders, including Gamma’s $48.0 million annualized guaranteed sales contract announced March 3rd 2010, and that shipping to retailers is expected to begin soon. Under the terms of the purchase orders, Gamma expects to begin receiving sales revenue by early September.

Joseph Cunningham, Gamma’s Chief Financial Officer, commented. “With the support of our major distribution partner, Gamma was able to secure highly specialized purchase order financing that has enabled the Company to manufacture and deliver product and generate sales virtually from a standing start. We are now in the process of securing additional capital and financing that will permit Gamma to quickly ramp up sales pursuant to purchase orders and purchase discussions that have been ongoing.”

On March 3, 2010, Gamma announced the Company had entered into a multi-year agreement (the “Agreement”) with one of North America’s leading wholesale distribution organizations to distribute the full line of Gamma products. The Agreement, which is evergreen in duration, provides for minimum monthly volume purchases of Gamma products at agreed upon pricing per SKU. The contracted terms prescribe a minimum purchase of 40,000 cases per month (after an initial ramp-up period) of Gamma’s branded products, which at full distribution equates to annualized sales revenue of approximately $48.0 million. Gamma’s distribution partner is a large wholesale distributor of branded consumer products in North America, and is credited with the enormous commercial success of many leading consumer brands.

Peter Cunningham, Gamma’s Chief Executive Officer, commented on the news. “We are extremely excited about this important milestone. Over the last two years, Gamma has finalized our product formulation and packaging, completed contract manufacturing and supply chain logistics, established critical distributor and retailer arrangements, and developed a comprehensive marketing and promotion program designed to stimulate consumer demand for our unique branded products. Our close cooperation with our manufacturing partners has enabled Gamma to achieve a unit cost profile designed to generate a profit margin exceeding 60%. Our major distribution partner has gone far beyond the role of a typical distributor, fully backing our commercial launch. Our aim for our branded products is the broadest possible distribution and we continue to work to put in place a network to achieve our distribution objectives. In the process, we have transformed Gamma as a company.”

About Gamma Pharmaceuticals Inc

For Immediate Release
LAS VEGAS, NV--(Marketwire - 06/15/10) - Gamma Pharmaceuticals, Inc. (Pinksheets:GMPM - News): Gamma Pharmaceuticals Inc. (OTCBB GMPM) announces an agreement with Mr. Checkout, a major national network of distributors for coverage in selected territories. The initial push will be in more than 600 outlets, with an estimated retail market value of $500,000 in the first year. Gamma has established a very effective network of distributor resources and direct to retail systems throughout key markets in USA and China. Mr. Checkout and Gamma may expand their distribution reach further, as mutually agreed, on a territory-by-territory basis.

This represents a significant push for Gamma whose brands are cited by consumers as being equal to or better than similar offerings from Pfizer Inc., Johnson & Johnson and Bayer. Gamma’s CEO Peter Cunningham commented, “This is another significant piece in our distribution profile in the US market. Retail chains are very supportive of Gamma’s promotional programs and have responded with immediate orders. We look forward to working with Mr. Checkout and will continue to seek distributors with consumer retail awareness and market reach.”

About Gamma Pharmaceuticals Inc

For Immediate Release
LAS VEGAS, NV--(Globe Newswire - 03/29/10)

Gamma Pharmaceuticals Inc.("Gamma" or the "Company") through its joint venture company, Holyfield Gamma Choice LLC, accepts the first purchase order for "Holyfield's Choice Water" from the Company's distribution partner. One day after issuing the purchase order to Gamma, the Company's distribution partner received purchase orders from clients for product placement in 1,500 retail outlets, 250 restaurants and approximately 2,000 vending machines. Gamma expects to book the revenue from this first transaction in the quarter ending June 30, 2010.

Peter Cunningham, a Holyfield Gamma Choice LLC management board member, stated, "The pace and scale of our capability to implement product roll-out is noteworthy. The joint venture with Holyfield International was announced March 1, 2010; the contract with our distribution partner was announced on March 3rd; on March 24th, Holyfield Gamma Choice LLC announced the roll-out of "The Holyfield Challenge" on college campuses; and, today, we are announcing placement of Holyfield's Choice products across three major commercial channels."

Dwayne Corbitt, a Holyfield Gamma Choice LLC management board member, added, "Holyfield's Choice Water is an Alkaline Water. Scientific studies conclude that Alkaline Water can offset the effects on the body's normal pH caused by exercise, diet, the environment, amongst other causes. Evander Holyfield has been drinking Alkaline Waters as part of his fitness and healthy lifestyle regime for several years. Holyfield Gamma Choice LLC brings Alkaline Water to the public for daily consumption through retail, restaurant and vending channels at competitive prices."

Holyfield Gamma Choice LLC is formulating and marketing an innovative line of vitamins and nutritional products utilizing Mr. Holyfield's expertise in nutrition and physical training and Gamma's formulation and marketing know-how. Holyfield Gamma Choice LLC products are labeled Holyfield Choice. Holyfield Gamma Choice LLC is closely integrated with Gamma's existing corporate infrastructure and distribution channels, and currently has four product lines and seven SKUs, with plans for expansion. Under the terms of the venture, Gamma will consolidate the joint venture's performance into Gamma's financials.

About Gamma Pharmaceuticals Inc

For Immediate Release
LAS VEGAS, NV--(Marketwire - 03/26/10)

Gamma Pharmaceuticals Inc. ("Gamma" or "the Company") initiates roll-out of "the Holyfield Challenge" on college campuses through its Joint Venture Company, Holyfield Gamma Choice, LLC. College students participating in the Holyfield Challenge are encouraged to improve academic performance, as well as quality-of-life and health parameters through a healthy body and improved lifestyle program that awards scholarships, jobs and other incentives to participants and their colleges. Holyfield Gamma Choice, LLC utilizes Evander Holyfield, the four-time World Boxing Heavy Weight Champion's expertise in nutrition and physical training and Gamma's formulation and marketing know-how to create and supply nutritional products to Holyfield Challenge participants along with wellness programs targeted at the college market. Livingstone College in Salisbury, North Carolina is the first campus to collaborate for the implementation of the Holyfield Challenge.

Peter Cunningham, a Holyfield Gamma Choice LLC management board member, stated, "Livingstone College has worked with Mr. Holyfield to align Holyfield Choice resources and goals with the objectives of the health and wellness components of their curriculum and campus life." Mr. Cunningham continued, "Holyfield Gamma Choice, LLC anticipates more than 100 college and university campuses will participate in the first year, making this a major healthy lifestyle contributor in communities across the country." Gamma Pharmaceuticals, Inc. views the college market as a strategic market in which to establish wellness habits and brand loyalty that will carry on throughout consumers' lives.

On March 1, 2010, Gamma announced the formation of a Joint Venture Company with Boxing World Heavyweight Champion Evander Holyfield. Mr. Holyfield is the only 4-time Boxing World Heavyweight Champion and in unaided focus groups is identified as one of the world's most recognized athletes. The joint venture, branded "Holyfield Choice," is formulating and marketing an innovative line of vitamins and nutritional products utilizing Mr. Holyfield's expertise in nutrition and physical training and Gamma's formulation and marketing knowhow. Holyfield Choice is closely integrated with Gamma's existing corporate infrastructure and distribution channels, and currently has four product lines and seven SKUs, with plans for expansion. Under the terms of the venture, Gamma will consolidate the joint venture's performance into Gamma's financials.

About Evander Holyfield

Evander Holyfield is a professional boxer from the United States and is the only 4-time World Heavyweight Champion earning him the nickname "The Real Deal." He is one of the most recognized athletes in the world. Outside of boxing, he has appeared in numerous television shows and movies including a 5th place finish on ABC's "Dancing with the Stars" in 2005. He is President of the Holyfield Foundation, created to help disadvantaged young people become healthy, successful and productive adults. The Holyfield Foundation strives to strengthen the lives of youth and their families by establishing and funding programs dedicated to their athletic, academic and spiritual development.

About Gamma Pharmaceuticals Inc

For Immediate Release
LAS VEGAS, NV--(Marketwire - 03/15/10)

Gamma Pharmaceuticals, Inc. ("Gamma" or the "Company") announced that it has retained Burnham Securities Inc., ("Burnham"), the New York based investment banking boutique, and Nelson Mullins Riley & Scarborough LLP ("Nelson Mullins"), the national general practice law firm founded in 1897, to assist and advise Gamma management ("Management") in a variety of corporate initiatives and to assist the Company in seeking financial and strategic alternatives.

Peter Cunningham, Gamma's Chief Executive Officer, commented on the engagements. "Gamma is at the most exciting point in the Company's history. After two years of challenges, where Management has had to bootstrap the Company forward to raise capital, formulate products, establish marketing and promotional platforms, and set up supply chain logistics, we have recently set in place several arrangements that position Gamma for potentially significant growth and profitability. Our previously announced ventures and agreements with Evander Holyfield, Jugular Inc., new distributors and an expanded retail customer base have transformed Gamma as a company. We are now rushing to confirm purchase orders and commission manufacturing to quickly ramp up to our contract minimums. As some commentators have said, 'the table for Gamma has been set.' The 'new' Gamma requires top-notch professional advisors to assist and advise Management in seeking financial and strategic alternatives designed to maximize shareholder value."

Randal Stephenson, Managing Director of Burnham Securities Inc., said, "We feel honored to assist and advise Gamma at this exciting time. The Company's recent initiatives have transformed Gamma almost overnight from a pre-revenue, developing business into a company with contractually guaranteed minimum sales volumes and annualized revenues of approximately $48 million. This fundamentally alters the Company's intrinsic value. Moreover, the new product lines under development with boxing legend Evander Holyfield and others are expected to generate additional sales volume and revenues significantly above these contract minimums. We are actively fielding numerous strategic inquiries and analyzing several financial and strategic alternatives, including a possible capital infusion by an equity sponsor, which is expected to create substantial additional shareholder value."

Joe Cunningham, Gamma's Chief Financial Officer, commented on the retention of Burnham. "We are very pleased to have a seasoned banker like Randal Stephenson and a venerable firm like Burnham as our investment bankers. Randal has been advising Gamma for the past two years through our development period, and he and Burnham were instrumental in guiding us through the several initiatives we recently announced. Now that the Company is positioned for substantial growth and profitability, Burnham's strong track record in debt and equity capital raising and mergers and acquisitions advisory will prove invaluable. Burnham is actively developing and investigating several financial and strategic alternatives designed to further increase the value of Gamma."

Joe Cunningham added about Nelson Mullins' engagement, "Nelson Mullins has proven to be exactly the legal advisor required by the 'new' Gamma. We just completed a flurry of joint ventures, long-term agreements and other corporate initiatives all of which are anticipated to be value-enhancing. Nelson Mullins' experience and commercial savvy helped us clarify, organize and conclude these sophisticated agreements and important initiatives. In addition, their calm hand supported our negotiations from start to finish. It is critical that we have a world class, sophisticated legal counsel like Nelson Mullins as Gamma continues to investigate opportunities, both here in the U.S. and overseas."

About Burnham Securities Inc.
Burnham Securities Inc. (http://www.burnhamfinancial.com/) is the investment banking unit of Burnham Financial Group located in New York. Burnham investment bankers have established themselves to be among the industry's most experienced, responsive and professional. Burnham's broad network of corporate and financial sponsor relationships, and its knowledge of the capital markets, allow the firm to shape strategic financial alternatives, suggest and structure business combinations, identify capital sources, negotiate terms and arrange injections of capital. As an integral part of Burnham Financial Group and the firm's 70-year history (together with predecessor firms), Burnham Securities Inc. blends relationship value with creativity during each assignment.

About Nelson Mullins Riley & Scarborough LLP
Nelson Mullins Riley & Scarborough LLP (http://www.nelsonmullins.com/), with more than 40 diversified practice areas, provides creative solutions to complex legal and business problems while offering value-added service to clients. Many Nelson Mullins clients, including growth companies, expanding local businesses, and major international companies, retain the Firm to provide all of their legal services. Other clients are national companies requiring assistance with specific regional or local legal matters. With more than 400 attorneys and government relations professionals practicing from offices in Atlanta, Boston, Tallahassee, West Virginia, Washington, D.C., and throughout the Carolinas, Nelson Mullins has strong roots in the business community and an appreciation for new directions in the business world.

-

About Gamma Pharmaceuticals Inc

For Immediate Release
Las Vegas, Nevada, March 9, 2010 -("Gamma" or the "Company") announced the formation of a joint venture company with Jugular, Inc. ("Jugular"), replacing the brand licensing agreement in place between Gamma and Jugular since 2007. The new company, Gamma Jugular, LLC ("Gamma Jugular") is closely integrated with Gamma's existing corporate infrastructure and distribution channels, and currently has three product lines and six SKUs with plans for expansion. Under the terms of the joint venture, Gamma will consolidate Gamma Jugular's performance into Gamma's financials.

Peter Cunningham, Gamma's Chief Executive Officer, commented on the initiative, "Forming Gamma Jugular is important to the Company in two significant ways. First, we improve corporate control by integrating Gamma's infrastructure with Jugular, Inc. on our exclusive product range. Second, we eliminated a substantial debt obligation payable to Jugular per our Licensing Agreement from 2007. We believe this will provide management with additional flexibility in the future." Mr. Cunningham continued, "We have worked for two years developing our Jugular product line of energy products and high performance vitamins and nutriceuticals. The leading edge products we have developed achieved an 85% 'willingness to purchase' after the first try. Today, we are embarking on a national and global expansion, details of which we will release in the weeks ahead. We expect great things from the Gamma Jugular, 'Go for the Jugular' campaign."

On March 3rd 2010, Gamma announced that it has entered into a multi-year agreement with one of North America's leading wholesale distribution organizations to distribute the full line of Gamma products, which at full distribution equates to an annualized value of approximately $48.0 million. The Company will utilize a portion of the distribution arrangement to accelerate the rollout of the Gamma Jugular product range.

About Gamma Pharmaceuticals Inc

For Immediate Release
LAS VEGAS, NV--(Marketwire - 03/03/10) - Gamma Pharmaceuticals, Inc. (Pinksheets:GMPM - News): Gamma Pharmaceuticals, Inc. ("Gamma" or the "Company") announced that it has entered into a multi-year agreement (the "Agreement") with one of North America's leading wholesale distribution organizations to distribute the full line of Gamma products. The Agreement, which is evergreen in duration, provides for minimum monthly volume purchases of Gamma products at agreed upon pricing per SKU. The contracted terms cover the sale of 40,000 cases per month of Gamma's branded products, which at full distribution equates to an annualized value of approximately $48.0 million. Gamma's new distribution partner is one of the largest wholesale distributors of branded consumer products in North America, and is credited with the enormous commercial success of many leading consumer brands.

Peter Cunningham, Gamma's Chief Executive Officer, commented on the agreement, "We are extremely pleased to have successfully contracted with such an accomplished distributor. The distributor and its retail network share Gamma's view that our products have great commercial appeal. This guarantee arrangement takes Gamma from the pre-revenue, pre-EBITDA company it has been over the past two years to a company with approximately $48 million in minimum annualized revenues, and enables Gamma's management and shareholders to look forward with more certainty in anticipating our growth and profitability." Mr. Cunningham added, "Gamma now has in place a distribution platform that truly complements the Company's product portfolio. Gamma can now successfully extend its commercial reach to more effectively attract additional retail accounts that will drive revenues in the US market for years to come."

About Gamma Pharmaceuticals Inc

For Immediate Release
LAS VEGAS, NV--(Marketwire - 02/25/10) - Gamma Pharmaceuticals, Inc. (Pinksheets:GMPM - News), a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally, today released a letter to shareholders from Peter Cunningham, Chief Executive Officer, providing investors with important announcements and Management's vision for the company for the remainder of 2010 and beyond.

Dear Shareholders:
It is my pleasure to write to you today to bring you details of multiple, concurrent corporate initiatives we are unveiling, which are designed to significantly expand Gamma's global market share and sales revenue in the vitamin, nutritional supplement and consumer healthcare market and, accordingly, the value to you, our shareholders. The difficult economic environment of the past two years delayed several of these initiatives, but also prompted Gamma Management to focus resources and position our products for maximum impact. It is our intent in the weeks and months ahead to provide our current investors regular updates as we execute on these initiatives.

As many of you know, during the past two years Gamma suffered set-backs which delayed our ability to execute the original business plan for the Company. Unfortunately, when our main funding provider defaulted on a substantial obligation to the Company, at the on-set of the global credit crisis, it forced Management to modify certain commercial arrangements and to renegotiate our purchase order and factoring credit facilities; ultimately effecting the execution of our initial strategy and impacting our timeline. However, Management used this period to establish multiple joint ventures, new distribution arrangements, new product formulations and product lines, and expanded marketing relationships that we believe should propel Gamma into an exciting new chapter of success.

In addition, while our customers and manufacturing partners have stood by the Company, Management adjusted its business model to be more effective in this new economy. We have reinforced relationships with our customers (both distributors and retailers), financing sources and manufacturers so that Gamma can focus on its core strengths of marketing and product formulation, creating significant new opportunities and reducing cost of goods by approximately 33%. In parallel, we have addressed the financial opportunities available to the Company. We believe all these initiatives should accelerate our growth and drive substantial revenue gains for years to come. Importantly, we have entered into a long-term, minimum purchase contract with a leading U.S. distribution partner to market and distribute Gamma products, with contractual minimum set to achieve annualized sales of approximately $48 million. This crucial initiative transforms Gamma from the pre-revenue, pre-EBITDA Company it has been over the past two years into a company with substantial minimum annual revenues, which enables us to look forward with more certainty in anticipating our growth and profitability. Management views this minimum threshold as a strong base upon which to build a comprehensive offering of product lines and brands and to exploit opportunities with enormous potential. As of this writing, our order book contains millions of dollars in purchase orders and a robust order pipeline.

Next week we will announce a global product development and marketing joint venture with a world-famous athletic personality. Gamma is the controlling owner of a global joint venture that will formulate, market and distribute a specialty line of vitamins, nutritional supplements and health related products branded by a world-famous athlete who is revered for his exceptional fitness and stamina. Our initial strategic plan utilizes Gamma Gel Delivery Technology® for four product lines appealing to fitness-minded individuals including serious competitors and athletes. Our contract distributors have expressed high interest in a comprehensive roll-out of this branded product line alongside other Gamma brands, which we will target tens of thousands of retail outlets. We are actively in discussion on additional opportunities to exploit Gamma's expertise in product formulation and marketing, and we intend to opportunistically add business units or joint ventures as our market profile develops.

We have streamlined our balance sheet and reorganized our businesses using Gamma Pharmaceuticals as a holding company for numerous health and nutritional initiatives. Our distribution contracts and support provided by our contract manufacturers, supply chain and retailers have enabled Gamma to organize marketing and formulation initiatives and to reorganize certain debt obligations. We have reorganized a debt obligation with the Jugular® license into a joint venture, enabling Gamma to eliminate substantial debt while not affecting Gamma's revenue or profitability. Gamma will continue as a product formulation and marketing company, thereby keeping our fixed costs low and focusing our resources on our highest value-added activities. Management believes this lean, focused approach is critical to maximizing shareholder value.

Our U.S. and global market positions are strong and improving and commanding the attention of retailers and end users alike. We is approached for media, promotion and public relations program launches at prices that are significantly less expensive than even one year ago. We are ready to launch our NBA, NHL, MLB and WNBA arena programs, Gamma Women Forum Series, sampling programs, point of sale and sweepstake programs at the retail level and now we have the distribution partners to keep our products moving through the retail channel. In today's economic environment, we anticipate costs savings on all corporate programs and will selectively seek additional opportunities. Recently, we secured trademark protection in China, and we are on track to expand our business in Southeast Asia including Hong Kong and China.

We have retained a leading middle-market investment bank and national law firm, significantly enhancing our financial, legal and administrative resources. During the past several months, Management has worked closely with its investment bankers and lawyers to finalize the initiatives discussed above. Our advisors have enabled us to more effectively negotiate, structure and execute more sophisticated transactions to drive our strategic initiatives. Further, given the rapidly evolving circumstances of the Company, our investment bankers are actively advising and assisting Gamma in identifying and considering various potential strategic and financial opportunities, including other potential joint ventures, acquisitions and capital raises.

To be certain, challenges remain, as in all businesses. Management has been extremely disappointed in the performance of our equity over the past 18 months, but is committed to driving shareholder value and to making every reasonable effort to ensure that the public has a full understanding of the tremendous opportunities at hand and those that will develop in the future. We believe this is a truly exciting time in Gamma's history.

I would like to close by thanking you for your confidence, patience and commitment to Gamma Pharmaceuticals. Our team has worked diligently to position our Company for future growth and profitability. I know of no other small company that has been able to marshal the resources that Gamma has at this time to enable us to make a substantial push into the market place and indelibly stamp our branded products on the consumer landscape. You can look forward to more frequent communication and we invite you to please contact us at our corporate headquarters should you have any questions or concerns or issues with what I have discussed here today.

I wish you a very successful 2010 and I hope that Gamma can be one stock you brag about owning.
Warmest regards,
/s/ Peter Cunningham

About Gamma Pharmaceuticals Inc

For Immediate Release
LAS VEGAS, NV--(Marketwire - 03/01/10) - Gamma Pharmaceuticals, Inc. (Pinksheets:GMPM - News): Gamma Pharmaceuticals, Inc. ("Gamma" or the "Company") announced the formation of a Joint Venture Company with Boxing World Heavyweight Champion Evander Holyfield. Mr. Holyfield is the only 4-time Boxing World Heavyweight Champion and in unaided focus groups is identified as one of the world's most recognized athletes. The joint venture, branded "Holyfield Choice," is formulating and marketing an innovative line of vitamins and nutritional products utilizing Mr. Holyfield's expertise in nutrition and physical training and Gamma's formulation and marketing knowhow. Holyfield Choice is closely integrated with Gamma's existing corporate infrastructure and distribution channels, and currently has four product lines and seven SKUs, with plans for expansion. Under the terms of the venture, Gamma will consolidate the joint venture's performance into Gamma's financials.

Evander Holyfield expressed great enthusiasm for his new venture with Gamma saying, "For several years I have searched for a partner to help me commercialize products that I know will work because I use the formulations and I live the program. Holyfield Choice represents the real Evander Holyfield and my personal expertise and passion for fitness -- at 47 years old I am more fit and energetic today than I was a decade ago. Gamma is the perfect partner for me and together we can make the world fighting fit."

Peter Cunningham, Gamma's Chief Executive Officer, commented on the initiative, "We believe the potential of the Holyfield's Choice brand is global and virtually limitless. Evander's truly remarkable fitness and stamina, especially at his age, is regarded with both wonder and admiration, and we believe consumers want to participate in his coveted 'fountain of youth.' Working closely with Evander, Gamma has specially formulated and dosed a complete line of supplements, vitamins and energy boosters that can form an important part of a health and fitness regimen designed to try to achieve the exceptional results that Evander 'The Real Deal' Holyfield has enjoyed for years."

Cunningham continued, "We're very excited and pleased to have this terrific opportunity with Evander come together. Both Gamma and the Holyfield organization have been working diligently refining our product formulation and taking the necessary steps to quickly roll out products and establish Holyfield Choice as a preferred consumer product. We have been in advance marketing discussions with the wholesale distribution channel and leading retailers, and the response has been remarkable. In addition, Evander will soon be launching the 'Holyfield Challenge,' a national fitness and health program aimed at school-age and college-age students that will be rolled out to secondary schools and colleges around the country. Holyfield Choice fitness, nutrition and supplement products will be a key element of this youth-oriented program. With our multi-channel, multi-product roll-out of the Holyfield Choice line now organized and beginning implementation, we eagerly anticipate an exciting future."

About Evander Holyfield

Evander Holyfield is a professional boxer from the United States and is the only 4-time World Heavyweight Champion earning him the nickname "The Real Deal." He is one of the most recognized athletes in the world. Outside of boxing, he has appeared in numerous television shows and movies including a 5th place finish on ABC's Dancing with the Stars in 2005. He is President of the Holyfield Foundation, created to help disadvantaged young people become healthy, successful and productive adults. The Holyfield Foundation strives to strengthen the lives of youth and their families by establishing and funding programs dedicated to their athletic, academic and spiritual development.

About Gamma Pharmaceuticals Inc

For Immediate Release
LAS VEGAS, NV--(Marketwire - 02/25/10) - Gamma Pharmaceuticals, Inc. (Pinksheets:GMPM - News), a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally, today released a letter to shareholders from Peter Cunningham, Chief Executive Officer, providing investors with important announcements and Management's vision for the company for the remainder of 2010 and beyond.

Dear Shareholders:
It is my pleasure to write to you today to bring you details of multiple, concurrent corporate initiatives we are unveiling, which are designed to significantly expand Gamma's global market share and sales revenue in the vitamin, nutritional supplement and consumer healthcare market and, accordingly, the value to you, our shareholders. The difficult economic environment of the past two years delayed several of these initiatives, but also prompted Gamma Management to focus resources and position our products for maximum impact. It is our intent in the weeks and months ahead to provide our current investors regular updates as we execute on these initiatives.

As many of you know, during the past two years Gamma suffered set-backs which delayed our ability to execute the original business plan for the Company. Unfortunately, when our main funding provider defaulted on a substantial obligation to the Company, at the on-set of the global credit crisis, it forced Management to modify certain commercial arrangements and to renegotiate our purchase order and factoring credit facilities; ultimately effecting the execution of our initial strategy and impacting our timeline. However, Management used this period to establish multiple joint ventures, new distribution arrangements, new product formulations and product lines, and expanded marketing relationships that we believe should propel Gamma into an exciting new chapter of success.

In addition, while our customers and manufacturing partners have stood by the Company, Management adjusted its business model to be more effective in this new economy. We have reinforced relationships with our customers (both distributors and retailers), financing sources and manufacturers so that Gamma can focus on its core strengths of marketing and product formulation, creating significant new opportunities and reducing cost of goods by approximately 33%. In parallel, we have addressed the financial opportunities available to the Company. We believe all these initiatives should accelerate our growth and drive substantial revenue gains for years to come. Importantly, we have entered into a long-term, minimum purchase contract with a leading U.S. distribution partner to market and distribute Gamma products, with contractual minimum set to achieve annualized sales of approximately $48 million. This crucial initiative transforms Gamma from the pre-revenue, pre-EBITDA Company it has been over the past two years into a company with substantial minimum annual revenues, which enables us to look forward with more certainty in anticipating our growth and profitability. Management views this minimum threshold as a strong base upon which to build a comprehensive offering of product lines and brands and to exploit opportunities with enormous potential. As of this writing, our order book contains millions of dollars in purchase orders and a robust order pipeline.

Next week we will announce a global product development and marketing joint venture with a world-famous athletic personality. Gamma is the controlling owner of a global joint venture that will formulate, market and distribute a specialty line of vitamins, nutritional supplements and health related products branded by a world-famous athlete who is revered for his exceptional fitness and stamina. Our initial strategic plan utilizes Gamma Gel Delivery Technology® for four product lines appealing to fitness-minded individuals including serious competitors and athletes. Our contract distributors have expressed high interest in a comprehensive roll-out of this branded product line alongside other Gamma brands, which we will target tens of thousands of retail outlets. We are actively in discussion on additional opportunities to exploit Gamma's expertise in product formulation and marketing, and we intend to opportunistically add business units or joint ventures as our market profile develops.

We have streamlined our balance sheet and reorganized our businesses using Gamma Pharmaceuticals as a holding company for numerous health and nutritional initiatives. Our distribution contracts and support provided by our contract manufacturers, supply chain and retailers have enabled Gamma to organize marketing and formulation initiatives and to reorganize certain debt obligations. We have reorganized a debt obligation with the Jugular® license into a joint venture, enabling Gamma to eliminate substantial debt while not affecting Gamma's revenue or profitability. Gamma will continue as a product formulation and marketing company, thereby keeping our fixed costs low and focusing our resources on our highest value-added activities. Management believes this lean, focused approach is critical to maximizing shareholder value.

Our U.S. and global market positions are strong and improving and commanding the attention of retailers and end users alike. We is approached for media, promotion and public relations program launches at prices that are significantly less expensive than even one year ago. We are ready to launch our NBA, NHL, MLB and WNBA arena programs, Gamma Women Forum Series, sampling programs, point of sale and sweepstake programs at the retail level and now we have the distribution partners to keep our products moving through the retail channel. In today's economic environment, we anticipate costs savings on all corporate programs and will selectively seek additional opportunities. Recently, we secured trademark protection in China, and we are on track to expand our business in Southeast Asia including Hong Kong and China.

We have retained a leading middle-market investment bank and national law firm, significantly enhancing our financial, legal and administrative resources. During the past several months, Management has worked closely with its investment bankers and lawyers to finalize the initiatives discussed above. Our advisors have enabled us to more effectively negotiate, structure and execute more sophisticated transactions to drive our strategic initiatives. Further, given the rapidly evolving circumstances of the Company, our investment bankers are actively advising and assisting Gamma in identifying and considering various potential strategic and financial opportunities, including other potential joint ventures, acquisitions and capital raises.

To be certain, challenges remain, as in all businesses. Management has been extremely disappointed in the performance of our equity over the past 18 months, but is committed to driving shareholder value and to making every reasonable effort to ensure that the public has a full understanding of the tremendous opportunities at hand and those that will develop in the future. We believe this is a truly exciting time in Gamma's history.

I would like to close by thanking you for your confidence, patience and commitment to Gamma Pharmaceuticals. Our team has worked diligently to position our Company for future growth and profitability. I know of no other small company that has been able to marshal the resources that Gamma has at this time to enable us to make a substantial push into the market place and indelibly stamp our branded products on the consumer landscape. You can look forward to more frequent communication and we invite you to please contact us at our corporate headquarters should you have any questions or concerns or issues with what I have discussed here today.

I wish you a very successful 2010 and I hope that Gamma can be one stock you brag about owning.
Warmest regards,
/s/ Peter Cunningham

About Gamma Pharmaceuticals Inc

For Immediate Release
Las Vegas, Nevada, January 21, 2010 - Gamma Pharmaceuticals Inc. (OTC: GMPM) announced today that the Company has signed a Distribution Agreement for Gamma’s branded product ranges. Under the Distribution Agreement, Gamma’s monthly sales will ramp-up to $3.4 million. The first monthly purchase order has been accepted with a value of $1.03 million. The Agreement marks a significant milestone for Gamma, as it provides a key piece in the Company’s North American Distribution plan. Gamma offers the industry’s most distinctive blend of brands, product forms, marketing programs and market message all focused on moving products through large and profitable sales channels. The order received includes the Company’s proprietary GELIbites®, GELIthins® and GELIcreams®. Peter Cunningham, Gamma CEO commented, “we are very excited to have contracted with such a capable partner and are working diligently to piece together a distribution network that will drive high volume, high value sale for years to come. We feel that 2010 will be a game changer for Gamma in every respect as we deliver on our potential and drive shareholder value. We have a deep sales pipeline that we will fill in the weeks and months ahead.”

About Gamma Pharmaceuticals Inc

For Immediate Release
October 29, 2009 (Las Vegas, NV and Beijing PRC)--Gamma Pharmaceuticals Inc. (the “Company”) (Ticker: GMPM) announced it has successfully completed the registration of six of the Company’s Brand Trademarks with The State Trademark Bureau of China. This important milestone is the conclusion of a two-year registration process and will provide Gamma with exclusivity of use and trademark protection on its commercial products in China.
Mr. Hao Zhang, Gamma’s Chief Marketing Officer and China Representative, stated, “We are pleased to have the proper protection for our brands and recourse should there be any infringement. The Chinese nutritional supplement market is growing rapidly and we need to have the correct legal protections as we push our brand identity.”

Gamma has a wholly-owned subsidiary in Hong Kong and a Representative office in Beijing to facilitate its Asian business. Gamma’s three founders have substantial business experience in Asia, having lived and worked there for nearly two decades. Gamma’s management views the rapidly growing Chinese market as a key growth driver for the Company and have budgeted approximately $13 million in revenues for 2010 from the region. Gamma’s intellectual property assets total nearly $6 million on the Company’s balance sheet. Management’s extensive Intellectual Property Management Program is designed to both protect these important assets and to grow their value.

About Gamma Pharmaceuticals Inc

For Immediate Release
October 28, 2009 (Las Vegas, NV)--Gamma Pharmaceuticals Inc. (the “Company”)(Ticker: GMPM) announced it has signed a Product Brokerage Agreement with J&A Lazier Racing LLC of California. Mr. Lazier, an accomplished Indy Car Driver, will benefit from Gamma’s Professional Grade vitamin supplements, nutritional and energy products to ensure peak athletic performance during the demanding Indy Car season. Gamma will make the products developed for the Indy Car race conditions available to consumers worldwide through Gamma’s global distribution platform.

Peter Cunningham, Gamma’s CEO stated, “We are thrilled to be in business with such an elite global athlete and personality. Gamma will be Mr. Lazier’s off-track pit crew. The objective is to keep Mr. Lazier in peak performance condition for the Indy Car season.” The Product Brokerage Agreement supports Gamma’s entry into the world of Indy Car Racing. Indy Car Racing is the premier motor sport in the US with a substantial domestic and global following. The sport fits Gamma’s global identity and up-market brand profile. The Indianapolis 500 is the largest single day sporting event in the world, attracting nearly 150 million television viewers and approximately 500,000 spectators. Gamma has built a full promotional and marketing program designed to attract motor sports fans to Gamma’s branded products.

About Gamma Pharmaceuticals Inc

For Immediate Release
October 13, 2009 (Las Vegas, NV)--Gamma Pharmaceuticals Inc. (the “Company”)(Ticker: GMPM) announced the Company has signed an Agreement for Purchase Order Financing and an Account Purchase (Factoring) facility. Combined, the financing package enables Gamma to amplify its manufacturing and retail resources in support of increased demand for the company’s products and its substantial purchase order pipeline. Gamma already has in place marketing programs to support sales of the Company’s own branded products nationwide. Joseph Cunningham, Gamma’s CFO, commented, “We have found a great group to work with and have designed a financing solution that will compress our days outstanding and provide the financial resources to ramp-up our revenue profile.” Last week, Gamma announced the signing of an Agreement-in-Principal (the ”Agreement”) with four-time World Heavyweight Champion, Evander Holyfield. The Agreement outlines a number of commercial opportunities including the development of the “Holyfield Theory” nutritional supplements and training programs as well as cross promotions and marketing support programs for Gamma’s own branded products.
About Gamma Pharmaceuticals Inc

For Immediate Release
October 5, 2009 (Las Vegas, NV)--Gamma Pharmaceuticals Inc. (the “Company”)(Ticker: GMPM) announced the Company has signed an Agreement-in-Principal (the ”Agreement”) with four-time World Heavyweight Champion Evander Holyfield. The Agreement, first made public by Mr. Holyfield at a press conference on September 25, 2009 announcing Holyfield’s health and green environmental initiatives, outlines a number of commercial opportunities including the development of the “Holyfield Theory” nutritional supplements and training programs as well as cross promotions and personal appearances with Gamma’s own branded products. Gamma will assist Holyfield in the final product definition and formulation and have worldwide marketing and distribution rights. Evander Holyfield is one of the most recognized athletes in the world today. At 46, he is seeking to unify the world heavyweight division. Holyfield’s next fight is set for November 8, 2009 in Seoul South Korea. His training techniques and nutritional program have kept Holyfield in peak physical condition and has made him the envy of his peers. Holyfield with Gamma will define and commercialize his unique brand in the form of vitamins and nutritional supplements and workout programs. The products will be available worldwide through Gamma’s global distribution platform. Peter Cunningham, Gamma’s CEO stated, “we are thrilled to be in business with such an elite global athlete and personality. He truly transcends demographic groups, cultures and boarders and fits our philosophy and company ethos perfectly. He is the “Real Deal” and we aim to make a significant impact with his brand in our marketplace, it’s a real knock out for Gamma.”

Mr. Holyfield commented, “Gamma came with the right set of ideas and platform to enable me to make a meaningful contribution by commercializing my nutritional philosophy and training ideas and distributing them to the widest market available. I’ve gained immeasurable knowledge on health and nutrition through my many years of training and I’m really excited to have Gamma in my corner as we bring the products to market.”

About Evander Holyfield
Evander Holyfield is a professional boxer from the United States and is the only 4-time World Heavyweight Champion earning him the nickname “The Real Deal”. He is one of the most recognized athletes in the world. Outside of boxing, he has appeared in numerous Television shows and movies including a 5th place finish in 2005 on ABC’s Dancing with the Stars. He is the President of the Holyfield Foundation, created to help disadvantaged young people become healthy, successful and productive adults. The Holyfield Foundation strives to strengthen the lives of youth and their families by establishing and funding programs dedicated to their athletic, academic and spiritual development.

About Gamma Pharmaceuticals Inc

For Immediate Release
July 23, 2009, Gamma Pharmaceuticals Inc. (the "Company") (OTC.BB:GMPM - News) today announced that effective at the open of business on July 24, 2009, the Company's common stock will be quoted on the Pink Sheets; it will cease being quoted on the OTCBB, as a result of a notice of OTCBB ineligibility received from FINRA due to the Company filing its Annual Report, Form 10-K, seven minutes late (5:37 pm EDT on July 15, 2009). However, the Company having filed, is considered current on its periodic reports with the Securities and Exchange Commission.

The FINRA notification was issued in accordance with NASD Rule 6530(e), which requires timely filing of periodic reports for continued quotation. The notification was issued in accordance with FINRA procedures because the Company did not timely file its Form 10-K for the year ended March 31, 2009.

As the Company's stock has already been quoted the Pink Sheet exchange since going public in January 2008, the Company is not anticipating a disruption for current shareholders or the investing public.

About Gamma Pharmaceuticals Inc